СоединенияАктивные ингредиентыGefitinib CAS 184475-35-2

Gefitinib CAS 184475-35-2  Product Information

Gefitinib CAS 184475-35-2 usages

Gefitinib, identified by its CAS number 184475-35-2, is a pharmaceutical drug employed for the therapeutic management of specific cancer variants, predominantly non-small cell lung cancer (NSCLC). Here are the primary applications of it:

1. Gefitinib is primarily given for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) that contains particular mutations in the epidermal growth factor receptor (EGFR) gene. These genetic alterations increase the cancer cells’ reliance on EGFR signalling for their growth and survival. Gefitinib is a pharmaceutical compound classified as an EGFR tyrosine kinase inhibitor (TKI) that hinders the functioning of EGFR, thereby impeding the proliferation and dissemination of malignant cells.

2. first therapeutic: Gefitinib can be utilised as a first therapeutic choice for individuals diagnosed with NSCLC who have EGFR mutations, especially those with exon 19 deletions or exon 21 (L858R) replacement mutations. It can be utilised either independently or in conjunction with other cancer drugs, such as chemotherapy or other targeted therapies, based on the distinct attributes of the malignancy and unique patient variables.

3. Maintenance Therapy: In certain instances, gefitinib can be employed as a kind of ongoing treatment after the first use of chemotherapy or other medicines that target the EGFR. Maintenance therapy seeks to extend the duration of disease control and postpone the advancement of the disease in patients who have shown positive responses to prior therapies.

4. Gefitinib can be employed as a second-line or subsequent treatment for patients with non-small cell lung cancer (NSCLC) who have seen progression after prior therapies, such as chemotherapy or other epidermal growth factor receptor (EGFR) inhibitors. It can offer a substitute therapy choice for people who cannot endure conventional medicines or whose cancer has gained resistant to other treatments.

5. Clinical Trials: Gefitinib is utilised in clinical trials to assess its efficacy in treating various forms of cancer or in conjunction with other pharmaceuticals or treatment methods. Clinical trials are conducted to evaluate the safety and effectiveness of novel treatment methods and to explore other applications of gefitinib in cancer treatment.

It is crucial to emphasise that gefitinib must only be administered under the guidance of a competent healthcare practitioner with expertise in cancer therapy. Decisions regarding therapy, such as choosing the right therapies and making adjustments to the dosage, should be made by considering individual patient factors, which include the unique characteristics of the cancer, the overall health condition, and the desired treatment outcomes.